Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$206.2M
Filings
729
Firms Hired
11
Active Period
1999–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; Drug pricing and reimbursement issues; Vaccine issues; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property and trade issues; International competition in biopharmaceuticals.
Client expense: $2,390,000 · Firm income: —
Matched citations: S. 2076
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · third_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · third_quarter · Firm: THE NICKLES GROUP, LLC
Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.
Client expense: — · Firm income: $70,000
Matched citations: H.R. 1
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · third_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.
Client expense: — · Firm income: $70,000
Matched citations: H.R. 1492
Biosimilars Access and Affordability Act
2026 · third_quarter · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 10628
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · third_quarter · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 8857
Chinese Military and Surveillance Company Sanctions Act of 2024
2026 · third_quarter · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Client expense: — · Firm income: $50,000
Matched citations: S.5571
National Defense Authorization Act for Fiscal Year 2027
2026 · third_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Client expense: — · Firm income: $40,000
Matched citations: H.R.8800
National Defense Authorization Act for Fiscal Year 2027
2026 · third_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Client expense: — · Firm income: $40,000
Matched citations: S.4784
Bipartisan Health Care Act
2026 · third_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Client expense: — · Firm income: $40,000
Matched citations: S.891
Drug Pricing. S.864: HELP Copays Act.
Client expense: — · Firm income: $50,000
Matched citations: S.864
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · second_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Drug pricing proposals. Pharmacy Benefit Manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation and ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D; Issues related to Most Favored Nation (MFN) drug pricing proposals.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · second_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Fairness for Rape Kit Backlog Survivors Act of 2021
2026 · second_quarter · Firm: MERCK & CO., INC.
S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing; Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients; International competition in biopharmaceuticals.
Client expense: $2,270,000 · Firm income: —
Matched citations: S. 1339
S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing; Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients; International competition in biopharmaceuticals.
Client expense: $2,270,000 · Firm income: —
Matched citations: S. 2076
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · second_quarter · Firm: THE NICKLES GROUP, LLC
Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.
Client expense: — · Firm income: $70,000
Matched citations: H.R. 1
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · second_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.
Client expense: — · Firm income: $70,000
Matched citations: H.R. 1492
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · second_quarter · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 8857
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · second_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to tax reform; R&D tax credit; international taxation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Client expense: — · Firm income: $40,000
Matched citations: H.R.1
National Defense Authorization Act for Fiscal Year 2027
2026 · second_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Client expense: — · Firm income: $40,000
Matched citations: H.R.8800
National Defense Authorization Act for Fiscal Year 2027
2026 · second_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Client expense: — · Firm income: $40,000
Matched citations: S.4784
Bipartisan Health Care Act
2026 · second_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Client expense: — · Firm income: $40,000
Matched citations: S.891
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · first_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to tax reform; R&D tax credit; international taxation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Client expense: — · Firm income: $40,000
Matched citations: H.R.1
Source: Senate LDA